Sartorius: First-Mover Advantage & Competitive Moat
Former R&D Director at Sartorius
inpractise.com/articles/sartorius-first-mover-advantage-in-bioanalytics-and-competitive-moat
Sartorius: First-Mover Advantage & Competitive Moat(July 31, 2025)
Former R&D Director at Sartorius
Interview Transcript
This is a snippet of the transcript.Contact Salesto get full access.
What has proven to make Sartorius so strong in this space? Why haven't other companies been able to break in?
It's been somewhat of a blind spot. No one else moved in that direction before Sartorius, and now others are trying to enter the same space. It was a niche between the leads and the actual bioprocessing. It wasn't recognized until a few years ago, but now it's shown to be a very valuable area. When something is valuable, competition inevitably follows.
This is a snippet of the transcript.Contact Salesto get full access.
Related Content
Mettler-Toledo: Pricing, Decentralization, & Vertical Integration
Former Executive at Mettler-Toledo
Danaher: Cytiva, HyClone, & Cell Culture Sales
Former Sales Specialist at Cytiva
Mettler-Toledo: Competition & Go-to-Market Strategy
Former Product Marketing Director at Mettler-Toledo
Danaher & Sartorius: Promising Yield
Former Head of Sales at Sartorius Stedim Biotech
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2025 IP 1 Ltd. All rights reserved.